MDPV

1. 2026-10-19issueIssued info_card
2. 2026-09-24srcStudies on the metabolism of the alpha-pyrrolidinophenone designer drug methylenedioxy-pyrovalerone (MDPV) in rat and human urine and human liver microsomes using GC-MS and LC-high-resolution MS and its detectability in urine by GC-MS
3. 2026-09-24srcNeuropharmacology of 3,4-Methylenedioxypyrovalerone (MDPV), Its Metabolites, and Related Analogs
4. 2026-09-24srcAbuse-related and abuse-limiting effects of methcathinone and the synthetic bath salts cathinone analogs MDPV, methylone and mephedrone on intracranial self-stimulation in rats
5. 2026-09-24srcBinge-like acquisition of 3,4-methylenedioxypyrovalerone (MDPV) self-administration and wheel activity in rats
6. 2026-09-24srcBehavioral economic analysis of the reinforcing effects of 'bath salts' mixtures: studies with MDPV, methylone, and caffeine in male Sprague-Dawley rats
7. 2026-09-24srcEffects of MDPV on dopamine transporter regulation in male rats. Comparison with cocaine
8. 2026-09-24srcIn vitro Phase I and Phase II metabolism of alpha-pyrrolidinovalerophenone (alpha-PVP), methylenedioxypyrovalerone (MDPV) and methedrone by human liver microsomes and human liver cytosol
9. 2026-09-24srcA case of fatal idiosyncratic reaction to the designer drug 3,4-methylenedioxypyrovalerone (MDPV) and review of the literature
10. 2026-09-24srcDeath following recreational use of designer drug 'bath salts' containing 3,4-Methylenedioxypyrovalerone (MDPV)
11. 2026-09-24src'Bath salts' and 'plant food' products: the experience of one regional US poison center
12. 2026-09-24srcPsychoactive 'bath salts' intoxication with methylenedioxypyrovalerone
13. 2026-09-24srcHyperthermia and multiorgan failure after abuse of 'bath salts' containing 3,4-methylenedioxypyrovalerone
14. 2026-09-24srcSubstituted methcathinones differ in transporter and receptor interactions
15. 2026-09-24srcFunctional connectivity, behavioral and dopaminergic alterations 24 hours following acute exposure to synthetic bath salt drug methylenedioxypyrovalerone
16. 2026-09-24srcNon-conserved residues dictate dopamine transporter selectivity for the potent synthetic cathinone and psychostimulant MDPV
17. 2026-09-24src3,4-methylenedioxypyrovalerone (MDPV): chemistry, pharmacology and toxicology of a new designer drug of abuse marketed online
18. 2026-09-24srcPowerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products
19. 2026-09-24srcLocomotor Stimulant and Rewarding Effects of Inhaling Methamphetamine, MDPV, and Mephedrone via Electronic Cigarette-Type Technology
20. 2026-09-24srcPolydrug fatal intoxication involving MDPHP: Detection and in silico investigation of multiple 3,4-methylenedioxy-derived designer drugs and their metabolites
21. 2026-09-24srcPostmortem tissue distribution of MDPV following lethal intoxication by 'bath salts'
22. 2026-09-24srcElectroconvulsive therapy improves persistent psychosis after repeated use of methylenedioxypyrovalerone ('bath salts')
23. 2026-09-24srcDeaths involving methylenedioxypyrovalerone (MDPV) in Upper East Tennessee
24. 2026-09-24srcLinear pharmacokinetics of 3,4-methylenedioxypyrovalerone (MDPV) and its metabolites in the rat: relationship to pharmacodynamic effects
25. 2026-09-24srcCardiovascular and locomotor effects of binary mixtures of common 'bath salts' constituents: Studies with methylone, methylenedioxypyrovalerone and caffeine in rats
26. 2026-09-24srcPotent rewarding and reinforcing effects of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV)
27. 2026-09-24srcPharmacological characterization of designer cathinones in vitro
28. 2026-09-24srcEmerging drugs of abuse: current perspectives on substituted cathinones
29. 2026-09-24srcClinical experience with and analytical confirmation of 'bath salts' and 'legal highs' (synthetic cathinones) in the United States
30. 2026-09-24srcSynthetic Cathinone and Cannabinoid Designer Drugs Pose a Major Risk for Public Health
31. 2026-09-24srcBehavioural, Pharmacokinetic, Metabolic, and Hyperthermic Profile of 3,4-Methylenedioxypyrovalerone (MDPV) in the Wistar Rat
32. 2026-09-24srcIntegrated Assessment of the Cardiotoxic and Neurobehavioral Effects of 3,4-Methylenedioxypyrovalerone (MDPV) in Zebrafish Embryos
33. 2026-09-24srcEmergency department visits after use of a drug sold as 'bath salts'--Michigan, November 13, 2010-March 31, 2011
34. 2026-09-24srcSympathomimetic syndrome, choreoathetosis, and acute kidney injury following 'bath salts' injection
35. 2026-09-24srcThe Psychotic Couple--Sharing Drugs or Delusions?
36. 2026-09-24srcMDPV legal status and scheduling history
37. 2026-09-24srcEMCDDA-Europol Joint Report on MDPV (3,4-methylenedioxypyrovalerone)
38. 2026-09-04issueIssued emergency
39. 2026-09-04issueIssued info_card
40. 2026-09-04issueIssued notice
41. 2026-06-04proposal42 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
42. 2026-06-04publicationPublication — backfill
43. 2026-04-25revisionRevision 1
44. 2026-04-25absenceSearched ClinicalTrials.gov for "MDPV methylenedioxypyrovalerone" — no results
45. 2026-04-25absenceSearched PubMed for "MDPV cathinone tramadol serotonin toxicity death interaction" — no results
46. 2026-04-25genGeneration — pipeline-v5 · with 1 morepipeline-v5
47. 2026-04-25rungeneration run

The same entries, as forms: six forms.